Common Vaginal Infections and Their Symptoms

Vaginal infections can be caused by various organisms and can present with different symptoms. Here are some common vaginal infections and their symptoms:

1. Candida albicans: This fungal infection can cause candidiasis, which presents with a thick, cottage-cheese yellowish discharge and pain upon urination. Treatment involves antifungal medication.

2. Normal discharge: A normal vaginal discharge is clear and mucoid, without smell or other concerning symptoms.

3. gonorrhoeae: This sexually transmitted infection caused by Neisseria gonorrhoeae can cause a thick green-yellow discharge, painful urination, and bleeding between periods.

4. Chlamydia: This common sexually transmitted infection is often asymptomatic but can eventually cause pain upon urination, vaginal/penile discharge, and bleeding between periods.

5. Bacterial vaginosis: This infection is caused by an overgrowth of bacteria in the vagina and presents with a grey, watery discharge with a fishy odor. Treatment involves antibiotics and topical gels or creams.

It is important to seek medical attention if you experience any concerning symptoms or suspect a vaginal infection.

To ensure maximum safety when switching from a traditional POP to COCP, it is recommended to use barrier contraception for 7 days while starting the combined oral contraceptive. This is the standard duration of protection required when starting this medication outside of menstruation. It is not necessary to use barrier contraception for 10 or 14 days, as the standard recommendation is 7 days. Using barrier contraception for only 3 days is too short, as it is the duration recommended for starting a traditional progesterone-only pill. While there may be some protection, it is still advisable to use additional contraception for 7 days to prevent unwanted pregnancy.

Special Situations for Combined Oral Contraceptive Pill

Concurrent antibiotic use has been a concern for many years in the UK, as doctors have advised that it may interfere with the effectiveness of the combined oral contraceptive pill. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines to abandon the extra precautions previously advised during antibiotic treatment and for 7 days afterwards. The latest edition of the British National Formulary (BNF) has also been updated to reflect this guidance, although precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

When it comes to switching combined oral contraceptive pills, the BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice. The FSRH’s Combined Oral Contraception guidelines state that the pill-free interval does not need to be omitted, while the BNF advises missing the pill-free interval if the progesterone changes. Given this uncertainty, it is best to follow the BNF’s advice.

Treatment Options for Menorrhagia

Menorrhagia, or heavy menstrual bleeding, can be a distressing condition for women. Current guidelines recommend the use of Mirena (IUS) as the first line of treatment, even for women who do not require contraception. Patient preference is important in the decision-making process, but IUS is still the preferred option.

If IUS is not suitable or preferred, there are several other treatment options available. Tranexamic acid, a medication that prevents the breakdown of blood clots, is a second-line option. Non-steroidal anti-inflammatory drugs (NSAIDs) and combined oral contraceptive pills can also be used to prevent the proliferation of the endometrium.

If these options are not effective, oral or injected progestogens can be used to prevent endometrial proliferation. Gonadotrophin-releasing hormone (GnRH) agonists, such as Goserelin, are also available as a last resort.

It is important for women to discuss their options with their healthcare provider and choose the treatment that is best for them. With the variety of options available, there is likely a treatment that can effectively manage menorrhagia and improve quality of life.

For non-pregnant women with vaginal thrush, the recommended first-line treatment is a single-dose of oral fluconazole. This is based on NICE guidelines for the diagnosis of vaginal candidiasis. The use of clotrimazole intravaginal pessary is only recommended if the patient is unable to take oral treatment due to safety concerns. Oral nystatin is not appropriate for this condition as it is used for oral candidiasis. While topical clotrimazole can be used to treat vaginal candidiasis, it is not the preferred first-line treatment and should only be used if fluconazole is not effective or contraindicated.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

Long-Term Complications of Vaginal Hysterectomy

Vaginal hysterectomy with antero-posterior repair is a common surgical procedure for women. However, it may lead to long-term complications such as enterocoele and vaginal vault prolapse. These conditions occur when the pelvic organs shift and push against the vaginal wall, causing discomfort and pain. While urinary retention may occur immediately after the surgery, it is not typically a chronic complication.

It is important for women who undergo vaginal hysterectomy to be aware of these potential complications and to discuss them with their healthcare provider. Regular check-ups and pelvic exams can help detect any issues early on and prevent further complications. Additionally, women can take steps to reduce their risk of developing these conditions by maintaining a healthy weight, avoiding heavy lifting, and practicing pelvic floor exercises. By being proactive and informed, women can minimize the impact of long-term complications and enjoy a better quality of life after surgery.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

For overweight or obese women with polycystic ovarian syndrome (PCOS) who are having difficulty getting pregnant, the initial approach is weight loss. If weight loss is not successful, either due to the woman’s inability to lose weight or failure to conceive despite weight loss, metformin can be used as an additional treatment.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is associated with high levels of luteinizing hormone and hyperinsulinemia. Management of PCOS is complex and varies depending on the individual’s symptoms. Weight reduction is often recommended, and a combined oral contraceptive pill may be used to regulate menstrual cycles and manage hirsutism and acne. If these symptoms do not respond to the pill, topical eflornithine or medications like spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another common issue associated with PCOS. Weight reduction is recommended, and the management of infertility should be supervised by a specialist. There is ongoing debate about the most effective treatment for infertility in patients with PCOS. Clomiphene is often used, but there is a potential risk of multiple pregnancies with anti-oestrogen therapies like Clomiphene. Metformin is also used, either alone or in combination with Clomiphene, particularly in patients who are obese. Gonadotrophins may also be used to stimulate ovulation. The Royal College of Obstetricians and Gynaecologists (RCOG) published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS.

The patient’s symptoms of dysmenorrhoea, dyspareunia, and subfertility are classic signs of endometriosis, a common condition where endometrial tissue grows outside of the uterus. The presence of uterosacral nodularity and tenderness further supports this diagnosis. Some patients with endometriosis may also experience urinary symptoms due to bladder involvement or adhesions. Uterine leiomyoma, or fibroid, is a common pelvic tumor that causes abnormal uterine bleeding, pelvic pressure and pain, and reproductive dysfunction. However, it does not typically present with uterosacral nodularity and tenderness on rectal examination. Interstitial cystitis causes urinary frequency and urgency, with pain relieved upon voiding. Pelvic inflammatory disease presents with fever, nausea, acute pain, malodorous vaginal discharge, and cervical motion tenderness/adnexal tenderness.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Surgical Options for Ovarian Cancer with Omental Involvement

When it comes to ovarian cancer with confirmed malignancy, the first-line surgery should be a total abdominal hysterectomy with bilateral salpingo-oophorectomy. This surgery should also include the removal of any omental involvement. Adjuvant chemotherapy may also be necessary. It’s important to note that ovarian cysts in postmenopausal women should always be assumed to be malignant. If there is omental metastasis, it confirms the diagnosis of ovarian cancer and surgery should include the removal of the ovaries, tubes, uterus, and omentum.

If a patient wants to preserve the possibility of future fertility, excision of the omental metastasis and unilateral oophorectomy could be considered. However, for older patients, this is an unnecessary risk. Total abdominal hysterectomy with bilateral salpingo-oophorectomy would have been the correct approach without omental involvement. Total abdominal hysterectomy with unilateral oophorectomy could be used in younger patients to maintain hormonal balance and avoid the need for HRT. However, there is a risk for recurrence, and for this patient, the omental lesion should still be removed. It’s safer to remove the uterus as well to reduce the risk of ovarian malignancy recurrence and potential uterine malignancy.

Women with PCOS who undergo IVF are at a higher risk of experiencing ovarian hyperstimulation syndrome. However, treatment failure can occur as a complication of any IVF treatment, regardless of whether the woman has PCOS or not. Complications such as chronic pelvic pain, Caesarean section delivery, and haemorrhage are not typically associated with IVF treatment.

Understanding Ovarian Hyperstimulation Syndrome

Ovarian hyperstimulation syndrome (OHSS) is a potential complication that can occur during infertility treatment. This condition is believed to be caused by the presence of multiple luteinized cysts in the ovaries, which can lead to high levels of hormones and vasoactive substances. As a result, the permeability of the membranes increases, leading to fluid loss from the intravascular compartment.

OHSS is more commonly seen following gonadotropin or hCG treatment, and it is rare with Clomiphene therapy. Approximately one-third of women undergoing in vitro fertilization (IVF) may experience a mild form of OHSS. The Royal College of Obstetricians and Gynaecologists (RCOG) has classified OHSS into four categories: mild, moderate, severe, and critical.

Symptoms of OHSS can range from abdominal pain and bloating to more severe symptoms such as thromboembolism and acute respiratory distress syndrome. It is important to monitor patients closely during infertility treatment to detect any signs of OHSS and manage the condition appropriately. By understanding OHSS and its potential risks, healthcare providers can work to minimize the occurrence of this complication and ensure the safety of their patients.